



KALC 2022

Korean Association for Lung Cancer International Conference
November 10-11, 2022 | Lotte Hotel World, Seoul, Korea

Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Small Cell Lung Cancer Patient's

Derizal¹, Roland Helmizar²

STP Trisakti, Jakarta¹. Department of Internal Medicine, Faculty
of Medicine Universitas Baiturrahmah, Padang, Indonesia²



Aims

- Lung cancer is a dangerous disease in the world. The results show that more men suffer from lung cancer than women. One of the efforts to treat this disease is chemotherapy. The results of the prognosis show that chemotherapy has an impact on longer survival and better quality of life. If the addition of an Immune Checkpoint Inhibitor in chemotherapy, a synergistic effect is seen and survival is better. However, there is controversy regarding the efficacy of this immunotherapy. This study aims to analyze the efficacy and safety of small cell lung cancer patients with immunotherapy and chemotherapy treatment.

Methods

- The method used is literature search through Pubmed/MEDLINE, Cochrane Library, EBSCO, and PROQUEST was conducted to find studies about the effectiveness of Line Immunotherapy in Combination with Chemotherapy for Small Cell Lung Cancer Patient's, of especially in terms of extensive SCLC Stadium. Two studies were selected and critically appraised. The data were then summarized descriptively.

Results

- The results showed that immunotherapy in the form of ipilimumab plus chemotherapy is better than OS (hazard ratio (HR) 0.64, 95% confidence interval (CI) 0.4-1.02; risk ratio (RR) 0.90, 95% and Reck (2013) found (HR: 0.95, 95% CI 0.59 -1.54, 95% CI 0.75 (0.48-1.19) than placebo plus chemotherapy. The combination of immunotherapy with chemotherapy was better than standard chemotherapy.

Conclusions

- In both the results suggest that immunotherapy with ipilimumab m suggests that PD-L1 inhibitors may be preferred. The results prove that Immune Checkpoint Inhibitors in first-line treatment for extensive-stage SCLC patients should be required

References

- Liu, L., Bai, H., Wang, C., Seery, S., Wang, Z., Duan, J., ... Wang, J. (2021). Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis. *Journal of Thoracic Oncology*, 16(7), 1099–1117. <https://doi.org/10.1016/j.jtho.2021.03.016>
- Wang, L., Yang, Y., Yu, J., Zhang, S., Li, X., Wu, X., ... Ai, B. (2022). Efficacy and safety of anti-PD-1/PD-L1 in combination with chemotherapy or not as first-line treatment for advanced non-small cell lung cancer: A systematic review and network meta-analysis. *Thoracic Cancer*, 13(3), 322–337. <https://doi.org/10.1111/1759-7714.14244>
- Zhang, X., Xu, Q., Yu, X., Huang, M., Li, S., Sheng, L., ... Liu, L. (2022). What Is Long-Term Survival and Which First-Line Immunotherapy Brings Long-Term Survival for Advanced Wild-Type Non-Small Cell Lung Cancer: A Network Meta-Analysis Based on Integrated Analysis. *Frontiers in Immunology*, 13(April). <https://doi.org/10.3389/fimmu.2022.764643>